View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 10, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Pierre FerraguÊ
  • Pierre FerraguÊ

Tesla in 2026: The dawn of Robotaxis. Top Pick.

The robotaxi market is at an inflection point, with Waymo, Tesla, and others expanding commercial operations this year. Tesla is best positioned to lead this transition. It benefits from three structural advantages versus peers: the lowest unit cost, a flexible supply base that avoids diminishing capital returns, and a massive fleet that accelerates learning and product improvement.

 PRESS RELEASE

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milesto...

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximat...

Pierre FerraguÊ
  • Pierre FerraguÊ

CES 2026: Nvidia the latest to validate Tesla's ADAS dominance

At CES yesterday, Nvidia unveiled the “Alpamayo” model family and development tools designed to speed up reasoning-driven autonomous vehicle deployment. This note updates our view following Mobileye's major US win and Nvidia's "Alpamayo" announcement.

Tesla Inc: 1 director

A director at Tesla Inc sold 60,000 shares at 445.396USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Blink Charging Powers Up Crypto Payments at DC Fast Charging Sites – E...

Blink Charging Powers Up Crypto Payments at DC Fast Charging Sites – Ethereum, Arbitrum, Polygon, and Base Supported Drivers can now pay with leading cryptocurrencies, delivering greater flexibility and convenience at Blink charging stations nationwide. Bowie, MD., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced the launch of the Company’s first phase in accepting cryptocurrency payments at select Blink-owned DC fast charging sites across ...

 PRESS RELEASE

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and we...

Pierre FerraguÊ
  • Pierre FerraguÊ

Tesla 4Q25: Pull-forwards of 3Q weigh on deliveries

Tesla reported 4Q25 production & deliveries earlier today. Please click the link below for our take on the numbers.

Anish Jog ... (+6)
  • Anish Jog
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig

Enterprise Products Partners LP: 1 director

A director at Enterprise Products Partners LP bought 15,000 shares at 32.089USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Anish Jog ... (+7)
  • Anish Jog
  • Chase Tohanczyn
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
Pierre FerraguÊ
  • Pierre FerraguÊ

Tesla 4Q25 preview: Pull-forwards of 3Q to weigh on deliveries this qu...

Tesla will report 4Q25 deliveries in early January. Please see the link below for our expectations.

 PRESS RELEASE

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Pro...

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a b...

Pierre FerraguÊ
  • Pierre FerraguÊ

The Tech Infrastructure Quarterly Bible 3Q25

We publish today our comprehensive quarterly bible: 242 pages of detailed analysis on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides:

Julie Boote
  • Julie Boote

PSA Autos / New Mobility: Japan's New EV Model Offensive

In this report, analyst Julie Boote reviews the 2025~2026 model line-up in the mainstream BEV segment for Japan’s automakers, focusing on Europe, North America [NA] and Japan, and assesses the appeal and competitiveness of the new models.

Pierre FerraguÊ
  • Pierre FerraguÊ

Tesla’s robotaxi secret weapon: customer vehicles

We published a deep dive on Wednesday outlining how we see Tesla stepping into the robotaxi opportunity. In today’s note, we focus on one of Tesla’s key advantages: customer-owned vehicles, and how they provide Tesla with a structural advantage versus peers.

Enterprise Products Partners L.P.: Key facts and statistics - LTM Sept...

A summary company profile, detailing Enterprise Products Partners L.P.’s business operations and financial highlights.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch